I received some encouraging news from Winsantor this morning that it plans to make its pirenzepine drug available through the state of Montana's enlightened "Right to Try" legislation which allows use of not-yet FDA approved drugs by those suffering from severe debilitating diseases not satisfactorily treatable by other means. Winsantor recently published its Phase 2a clinical trial results in the highly respected journal Lancet, demonstrating both safety and efficacy. This is the first drug that shows the ability to actually modify the underlying causes of the disease rather than merely treat symptoms, such as pain, which the FDA, to the detriment of all of us, has chosen to prioritize for the last several decades. Winsantor has indicated that the drug may become available at state- designated Experimental Treatment Centers in Montana as early as this summer. Applicants will need statements from their physicians attesting to their neuropathic conditions and their resistance to other treatment modalities and, of course, they will need to provide informed consent. Patients will have to travel to Montana. Treatment costs will not be covered by insurance. Meanwhile, Winsantor will continue to pursue phase 3 studies, but these may take years to complete and. thanks to FDA's misplaced priorities. will prove highly costly.